RxDoctor Payments DataLook up a doctor →

James Scott, MD

Diagnostic Neuroimaging · Ormond Beach, FLNPI 1952321671

Payments from drug & device makers

$4,740,749in general payments, 2019–2025

Across 1,280 payments — averaging $3703.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3.8M
  • EMD Serono, Inc.$298K
  • Adamas Pharmaceuticals, Inc.$141K
  • Eli Lilly$103K
  • Janssen Research & Development, LLC$100K
  • Alkermes, Inc.$87K
  • plus $189K from 54 others
$4,846in research payments, 2019–2025

Across 3 payments — averaging $1615.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K
  • Hexal AG$800

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis130$3,823,646
EMD Serono, Inc.134$298,123
Adamas Pharmaceuticals, Inc.59$140,697
Eli Lilly5$102,788
Janssen Research & Development, LLC25$99,571
Alkermes, Inc.35$86,703
Biogen78$80,612
Hexal AG2$30,500
Genentech, Inc.4$23,000
Argenx US, Inc.29$16,100
Teva Pharmaceuticals USA, Inc.45$12,555
Sunovion Pharmaceuticals Inc.22$5,851
Mallinckrodt Hospital Products Inc.19$5,423
AbbVie(2 entities)150$2,271
Ares Trading SA10$850
Pfizer51$836
Sanofi38$834
MDD US Operations, LLC17$780
CSL Behring29$747
Amgen(2 entities)33$694
UCB, Inc.24$664
Hoffmann-la Roche Limited2$587
Eisai Inc.18$504
AstraZeneca22$495
Bristol Myers Squibb25$445
Genentech USA, Inc.26$426
Acadia Pharmaceuticals Inc22$361
SK Life Science, Inc.13$340
Acorda Therapeutics, Inc17$314
Lilly USA, LLC14$304
Jazz Pharmaceuticals Inc.13$295
Greenwich Biosciences, Inc.17$282
Biohaven Pharmaceutical Holding Company Ltd.14$266
Vanda Pharmaceuticals Inc.10$223
Neurocrine Biosciences, Inc.8$215
Otsuka America Pharmaceutical, Inc.9$213
Corium, LLC9$199
Takeda Pharmaceuticals U.S.A., Inc.8$199
ANI Pharmaceuticals, Inc.7$180
Amneal Pharmaceuticals LLC8$151
Banner Life Sciences, LLC5$121
Avanir Pharmaceuticals, Inc.6$112
Lundbeck LLC6$112
Impel Pharmaceuticals Inc.5$106
GE HealthCare5$105
Biohaven Pharmaceuticals, Inc.5$86
Merck2$78
Scilex Pharmaceuticals Inc.4$73
Grifols USA, LLC3$71
TG Therapeutics, Inc.3$64
Neurelis, Inc.3$54
Mallinckrodt Enterprises LLC3$50
Johnson & Johnson3$49
E.r. Squibb & Sons, L.L.C.3$42
Chiesi USA, Inc.2$32
Catalyst Pharmaceuticals, Inc.1$30
Tanabe Pharma America, Inc.2$29
Avion Pharmaceuticals2$29
Portola Pharmaceuticals, LLC2$25
Cycle Pharmaceuticals Inc2$23

How this compares

Too few diagnostic neuroimaging providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$418,345
Medicare patients
1,090
Services billed
3,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other diagnostic neuroimaging in Ormond Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →